Quectel’s Ultra-high Bandwidth 5G R16 Module Certified for Use on T-Mobile’s 5G and LTE-A Networks
14.9.2022 18:41:00 EEST | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, has announced that its 5G NR module RM520N-GL, compliant with 3GPP Release 16 (R16) standards, has been certified to operate on T-Mobile’s 5G and LTE-A networks in the United States.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220829005280/en/
Quectel's 5G module RM520N-GL and its IoT application scenarios (Photo: Business Wire)
With this certification, RM520N-GL customers can commercially deploy their home gateways, industrial routers, industrial automation devices, unmanned delivery vehicles, robots, drones, consumer and industrial laptops and other next generation IoT applications on T-Mobile’s 5G and LTE-A networks.
“We are thrilled to see that Quectel has made further significant progress in 5G, as our module supporting 5G R16 features has gained this important certification in the North American market,” said Norbert Muhrer, President and CSO of Quectel. “This confirms our commitment to drive innovation and provide our global customers with highly reliable, best-in-class IoT solutions, which will help accelerate the next wave of 5G IoT applications.”
Based on Qualcomm’s SDX62 platform, the RM520N-GL supports both 5G NSA and SA modes, as well as R16 enhanced features such as ultra-high bandwidth, millisecond-level latency, 5G network slicing and ultra-reliability.
Targeting global markets, this module is designed to support 28 major sub-6GHz bands worldwide (n1/ 2/ 3/ 5/ 7/ 8/ 12/ 13/ 14/ 18/ 20/ 25/ 26/ 28/ 29/ 30/ 38/ 40/ 41/ 48/ 66/ 70/ 71/ 75/ 76/ 77/ 78/ 79), is backwards compatible with LTE-A/3G networks and features integrated GNSS for location services. This highly integrated module can significantly enhance customers' global IoT deployments.
Designed in an industry-standard M.2 form factor, the dimensions of the RM520N-GL are 30.0mm x 52.0mm x 2.3mm, making it pin-to-pin compatible with Quectel’s 5G module RM50xQ series, LTE-A Cat 6 module EM06/ EM060K series, Cat 12 modules EM12/ EM12xR/ EM120K series and Cat 16 module EM160R-GL, which facilitates easy network upgrades of customer devices.
The RM520N-GL supports downlink and uplink NR 2 x Carrier Aggregation (CA) and all three combinations of sub-6GHz time division duplex (TDD) and frequency division duplex (FDD) CA, including CA of FDD+TDD, FDD+FDD and TDD+TDD. This ensures greater 5G coverage, capacity and throughput by enabling the combination of available 5G spectrum assets. These features enable the RM520N-GL to have maximum downlink rates of up to 3.4Gbps and maximum uplink rates of up to 900Mbps. These data rates meet the needs of industry applications requiring enhanced mobile broadband and reliable communication capabilities, such as fixed wireless access (FWA), mobile broadband equipment and industrial automation.
Featuring a rich set of internet protocols, the RM520N-GL supports multiple optional functions including eSIM and VoLTE and integrates USB 3.1/ PCIe 3.0 super speed interfaces.
In addition to the T-Mobile approval, Quectel’s RM520N-GL has also achieved worldwide certification from GCF, PTCRB, CE, CCC, RCM, FCC and IC.
In order to help customers simplify their designs, Quectel also provides a full range of off-the-shelf and customized 5G antennas which boost wireless connectivity significantly. IoT developers can bundle the RM520N-GL module with Quectel’s antennas and pre-certification services, reducing both cost and time-to-market for their 5G devices.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth® modules, antennas and IoT connectivity. With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.Quectel.com, LinkedIn, Facebook, and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220829005280/en/
Contact information
Media
Ashley Liu – media@quectel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom